Yasuhiro Takeuchi

Yasuhiro Takeuchi's AcademicInfluence.com Rankings

Yasuhiro Takeuchi

Computer Science

#11677

World Rank

#12403

Historical Rank

Computational Linguistics

#2958

World Rank

#2992

Historical Rank

Machine Learning

#5366

World Rank

#5436

Historical Rank

Artificial Intelligence

#5786

World Rank

#5873

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Yasuhiro Takeuchi's Degrees

PhD Computer Science University of Tokyo
Masters Computer Science University of Tokyo
Bachelors Computer Science University of Tokyo

Similar Degrees You Can Earn

Why Is Yasuhiro Takeuchi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Yasuhiro Takeuchi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis (2003) (1631)
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. (2004) (1392)
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia (2001) (1317)
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. (2002) (640)
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. (2004) (426)
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. (2002) (411)
Association between activating mutations of calcium-sensing receptor and Bartter's syndrome (2002) (359)
Ghrelin Directly Regulates Bone Formation (2004) (299)
Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways (2006) (295)
Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade (2003) (287)
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. (2005) (199)
An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study (2018) (190)
Central control of bone remodeling by neuromedin U (2007) (180)
A microRNA regulatory mechanism of osteoblast differentiation (2009) (159)
Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. (2004) (157)
Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. (2003) (156)
Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. (1999) (147)
The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas (2015) (146)
Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans (2007) (137)
Targeted ablation of Fgf 23 demonstrates an essential physiological role of FGF 23 in phosphate and vitamin D metabolism (2004) (137)
Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in Mice* (2002) (130)
The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. (2016) (109)
Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. (2014) (98)
Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. (2000) (98)
Stimulation of Smad1 Transcriptional Activity by Ras‐Extracellular Signal‐Regulated Kinase Pathway: A Possible Mechanism for Collagen‐Dependent Osteoblastic Differentiation (2002) (97)
Runx1 and Runx2 cooperate during sternal morphogenesis (2010) (85)
Receptor Tyrosine Kinases Inhibit Bone Morphogenetic Protein‐Smad Responsive Promoter Activity and Differentiation of Murine MC3T3‐E1 Osteoblast‐like Cells (2003) (84)
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period (2019) (83)
Reduced Expression of Interleukin‐11 in Bone Marrow Stromal Cells of Senescence‐Accelerated Mice (SAMP6): Relationship to Osteopenia with Enhanced Adipogenesis (1998) (82)
Comparison of two assays for fibroblast growth factor (FGF)-23 (2005) (81)
Vitamin K(2) inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. (2000) (78)
Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. (1999) (75)
Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. (1996) (72)
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. (1999) (71)
A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. (1999) (68)
An adult patient with severe hypercalcaemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium‐sensing receptor (1999) (64)
Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib. (1996) (63)
High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. (2009) (62)
Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients (2003) (61)
Effects of 1-year treatment with fluvastatin or pravastatin on bone. (2001) (57)
Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. (2011) (55)
The distinct role of the Runx proteins in chondrocyte differentiation and intervertebral disc degeneration: findings in murine models and in human disease. (2008) (52)
Surgical management and outcomes in patients with Cushing disease with negative pituitary magnetic resonance imaging. (2012) (52)
Acetyl tributyl citrate, the most widely used phthalate substitute plasticizer, induces cytochrome p450 3a through steroid and xenobiotic receptor. (2011) (50)
Pathogenesis and diagnostic criteria for rickets and osteomalacia—proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society (2015) (48)
Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro1. (1999) (41)
Therapeutic outcomes of transsphenoidal surgery in pediatric patients with craniopharyngiomas: a single-center study. (2018) (39)
Pathogenesis and diagnostic criteria for rickets and osteomalacia - proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society. (2015) (39)
Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia (2020) (30)
Therapeutic outcomes in patients undergoing surgery after diagnosis of Cushing's disease: A single-center study. (2015) (28)
Fibroblast growth factor (FGF)23 in patients with acromegaly. (2007) (27)
Hypoglycemic coma in a patient with anorexia nervosa coincident with acute exacerbation of liver injury induced by oral intake of nutrients. (2010) (27)
Inactivating Mutations of Calcium-Sensing Receptor Results in Parathyroid Lipohyperplasia (2001) (26)
Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma. (2015) (25)
Decreased AP‐1 Activity and Interleukin‐11 Expression by Bone Marrow Stromal Cells May Be Associated With Impaired Bone Formation in Aged Mice (2003) (25)
1,25-dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis. (2005) (24)
A family of autosomal dominant hypocalcemia with an activating mutation of calcium-sensing receptor gene. (2003) (22)
Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism (2017) (21)
Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro. (2002) (20)
GH deficiency in patients after cure of acromegaly by surgery alone. (2011) (19)
High incidence of obesity and elevated serum immunoreactive insulin level in patients with paravertebral ligamentous ossification: A relationship to the development of ectopic ossification (1989) (17)
Transsphenoidal cyst cisternostomy with a keyhole dural opening for sellar arachnoid cysts: technical note (2014) (17)
Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy. (2008) (16)
Outcomes of three-Tesla magnetic resonance imaging for the identification of pituitary adenoma in patients with Cushing's disease. (2019) (15)
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension (2021) (15)
Recurrence of primary hyperparathyroidism following spontaneous remission with intracapsular hemorrhage of a parathyroid adenoma (2008) (15)
Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. (2013) (14)
Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute. (2013) (14)
Coincidence of multiple endocrine neoplasia type 2A with acromegaly. (2010) (14)
The Asian Federation of Osteoporosis Societies' call to action to improve the undertreatment of osteoporosis in Asia (2017) (12)
A large functioning parathyroid cyst in a patient with multiple endocrine neoplasia type 1. (2013) (12)
The Asian Federation of Osteoporosis Societies' call to action to improve the undertreatment of osteoporosis in Asia (2017) (12)
Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23 (2021) (12)
The USP 8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing ’ s disease (2015) (12)
Symptomatic hyponatremia after voluntary excessive water ingestion in a patient without psychiatric problems. (2007) (11)
Parathyroid Hormone‐Related Protein Induced Coupled Increases in Bone Formation and Resorption Markers for 7 Years in a Patient With Malignant Islet Cell Tumors (2002) (10)
Pitfalls in early biochemical evaluation after transsphenoidal surgery in patients with acromegaly. (2017) (10)
[Parathyroid hormone (PTH)]. (1999) (9)
Scalp hair loss after transsphenoidal adenomectomy in patients with acromegaly (2013) (8)
The Interaction of Acute‐Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial (2021) (8)
Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor‐Induced Osteomalacia: Outcome of a Retrospective Surveillance (2022) (7)
[Innovation of bisphosphonates for improvement of adherence.] (2017) (7)
[Anabolic effects of statin and beta-blocker on bone metabolism]. (2004) (7)
Retraction Note: Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade (2014) (6)
Executive summary of clinical practice guide on fracture risk in lifestyle diseases (2020) (6)
Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study (2021) (6)
[Familial isolated hypoparathyroidism]. (2006) (6)
Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study (2015) (6)
New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide (2014) (6)
Ultrasonographic evaluation of parathyroid hyperplasia in multiple endocrine neoplasia type 1: Positive correlation between parathyroid volume and circulating parathyroid hormone concentration (2015) (6)
[New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis]. (2009) (5)
[Metabolic bone diseases in patients with diabetes mellitus]. (2006) (5)
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation (2018) (5)
Seasonal variation of urinary excretion of total metanephrines. (1976) (4)
Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide (2015) (4)
[Treatment of osteoporosis with PTH]. (2014) (4)
[Current Topics on Vitamin D. Treatment of osteoporosis with eldecalcitol: Its therapeutic efficacy and adverse effect on renal function]. (2015) (4)
Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study (2019) (4)
Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma? (2020) (4)
after successful pituitary surgery if pancreatic β-cell function is preserved (2011) (3)
[The role of PPAR gamma for the osteoblastic differentiation]. (2004) (3)
[Hormones and osteoporosis update. Possible roles of pituitary hormones, TSH and FSH, for bone metabolism]. (2009) (3)
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study (2022) (3)
How different is the once-weekly teriparatide from the daily one or the same? (2019) (3)
A Silent Follicle-Stimulating Hormone-Producing Pituitary Adenoma in a Teenage Male (2011) (3)
Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study (2020) (3)
[Possible involvement of pituitary hormones in bone metabolism]. (2013) (3)
Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis (2018) (3)
[Combination or sequential treatment using PTH and anti-resorption therapies]. (2012) (2)
[A case of idiopathic portal hypertension supervening on SLE (systemic lupus erythematosus)--a study on the possible role of SLE in the pathogenesis of IPH]. (1986) (2)
Primary aldosteronism presenting with an atypical aldosterone-renin ratio in the acute phase of cerebral hemorrhage. (2015) (2)
Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study (2022) (2)
Romosozumab and cardiovascular safety in Japan (2021) (1)
[Diabetes mellitus and osteoporosis. Therapeutic strategy for osteoporosis in patients with diabetes mellitus]. (2012) (1)
[Differential diagnosis of hypercalcemia]. (2007) (1)
[Do thiazolidinediones harm skeletal integrity?]. (2008) (1)
Hidden culprit of primary hyperparathyroidism. (2012) (1)
[Updates on Lifestyle-Related Diseases and Bone Metabolism. A possible involvement of vitamin D, a pivotal player in bone metabolism, in lifestyle-related diseases]. (2014) (1)
[Overview: derangement of bone metabolism in diabetes mellitus]. (2009) (1)
Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study. (2016) (1)
[Updates on rickets and osteomalacia: etiology and pathophysiology of osteomalacia]. (2013) (1)
[Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis]. (2011) (1)
A Case of Methimazole-Induced Acute Pancreatitis With an HLA Allele Causing Antithyroid Drug-Induced Agranulocytosis (2022) (1)
[Control of bone remodeling by bone anabolic drugs.] (2017) (1)
Tumoral calcinosis in a patient with hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome undergoing hemodialysis (2015) (1)
Effect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study (2021) (1)
GH-induced LH hyporesponsiveness as a potential mechanism for hypogonadism in male patients with acromegaly. (2021) (1)
[Parathyroid and bone. Skeletal derangement in patients with primary hyperparathyroidism]. (2007) (1)
[Rickets/Osteomalacia. Treatment of vitamin D deficiency in adults.] (2018) (1)
[Bone metabolism in metabolic syndrome and its treatment]. (2005) (1)
Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression (2021) (1)
[Pathophysiology in rickets/osteomalacia]. (2007) (1)
Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide (2015) (1)
[How do bisphosphonates improve bone quality?]. (2004) (1)
[How to use JSLM2009 guideline on the bedside teaching and learning in teaching hospitals]. (2011) (0)
6. New Progress of Bisphosphonate and New Drugs (2008) (0)
[Where do SERMs stand in the light of clinical application?]. (2007) (0)
Mechanisms for bone mineralization. (1999) (0)
[Effects of drugs for lifestyle-related diseases on bone metabolism]. (2011) (0)
[Control of bone remodeling by nervous system. Possible roles of pituitary hormones for bone metabolism]. (2010) (0)
[Pathogenesis of hypophosphatemia]. (2016) (0)
Bone and mineral disorders with advancing age (2003) (0)
[How is bone remodeling regulated?]. (2009) (0)
[Anti-osteoporosis drugs : their characteristics and evidence for anti-fracture efficacy]. (2012) (0)
Response to the letter from Otsuka et al. Trends in the prevalence of underweight in women across generations in Japan (2021) (0)
Clinical and histological characteristics of giant GH producing pituitary adenomas (2012) (0)
[Diagnostic criteria and limitation of pancreozymin-secretin test]. (1974) (0)
[Influence of anti T3 autoantibody on free T3 measurements]. (1984) (0)
[Anti-osteoporotic drugs and energy metabolism.] (2018) (0)
methyltransferase expression in invasive macroadenomas of Cushing's disease (2009) (0)
[Secondary osteoporosis UPDATE. How to diagnose secondary osteoporosis and disorders presenting low bone mineral density]. (2010) (0)
[Calcium-phosphorus metabolic disorders and the primary care (discussion)]. (2007) (0)
[Hypothyroidism with serum anti-T3 autoantibody--a case report]. (1983) (0)
[Aging and homeostasis. Management of disorders in bone and calcium metabolism associated with ageing.] (2017) (0)
[Cell adhesion molecule in osteobrast biology]. (2002) (0)
[Treatment of osteoporosis. Bisphosphonates]. (2005) (0)
[Bone metabolism and cardiovascular function update. Effects of drugs for lifestyle-related diseases on bone metabolism]. (2014) (0)
Sponsors: Symposium on Biomathematics 2015 (2016) (0)
[Cytokines in bone diseases. Involvement of cytokines in bone metastasis]. (2010) (0)
Author response for "Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia" (2020) (0)
[Genetic impairments of Wnt signaling pathways in hereditary high bone mass syndrome and sclerostosis diseases]. (2013) (0)
[Endocrine and Metabolic Emergencies: Points of Initial Management. Topics: IV. Emergency medical care for patients with hypercalcemia or hypocalcemia]. (2016) (0)
[Endocrinological examinations in patients with parathyroid tumors]. (2011) (0)
Special issue : Calcium.Clinic of bone metabolism abnormality.1.Basic matters.3.Differential diagnosis on hypercalciuria. (1993) (0)
[Assessment of bone quality with metabolic bone markers]. (2007) (0)
[FGF receptor and FGF signaling pathways]. (2005) (0)
[111th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: 17. Emerging clinical questions of calcium metabolism disorders and promising therapeutic approaches to them]. (2014) (0)
Author response for "The Interaction of Acute‐Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial" (2021) (0)
Case series of diabetic ketoacidosis as the first presentation of 860 patients with acromegaly (2012) (0)
Recent Progress in the Development of Osteoporosis Drugs (2018) (0)
[Hepatocellular carcinoma in patients with metabolic liver disease]. (2001) (0)
Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies (2023) (0)
List of reviewers 2015–2016 (2016) (0)
[Progress and problems in oral bisphosphonate]. (2014) (0)
[Clinical aspects of calcium metabolism disorders of the bone. I. Basic topics. 3. Differential diagnosis of hypercalciuria]. (1993) (0)
1. How to Prevent Fracture with Anti-osteoporosis Drugs: an Update (2014) (0)
Systemic Control of Bone Formation (1998) (0)
[Secondary osteoporosis. Clinical approach to secondary osteoporosis.] (2018) (0)
[Clinical evaluation of hepatic bruit audible in patients with alcoholic hepatitis]. (1998) (0)
[Anti-osteoporotic drugs and their interactions with multiple organs]. (2016) (0)
[How does bone mass decrease with advancing age?]. (2004) (0)
Challenges in the functional diagnosis of thyroid nodules before surgery for TSH-producing pituitary adenoma (2021) (0)
Recent progress in osteoporosis treatment (IBMS/JSBMR joint meeting 2013) (2013) (0)
[Endocrine diseases: progress in diagnosis and treatments. Topics: IX. Recent topics; 1. How to prevent fracture with antiosteoporosis drugs: an update]. (2014) (0)
Efficacy, safety and pitfalls of glucocorticoid therapy for patients with autoimmune hypophysitis (2020) (0)
Preface: Symposium on Biomathematics 2015 (2016) (0)
[Endocrine disease: progress in diagnosis and treatment. Topics: II. Progress in treatment; 5. Role of parathyroid hormone in bone metabolism and its clinical implication]. (2012) (0)
[Statins as possible therapeutic tools for osteoporosis]. (2004) (0)
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period (2019) (0)
[How anti-osteoporotic drugs work to improve bone metabolism]. (2015) (0)
VII. Hypophophatemia and Endocrine Diseases (2020) (0)
[Up-and-coming therapeutics for osteoporosis]. (2011) (0)
[Treatment with vitamin D metabolites for rickets/osteomalacia]. (2003) (0)
[Clinical approach to patients with hypocalcemia]. (2007) (0)
Successful Treatment of Amiodarone-induced-thyrotoxicosis with Glucocorticoid in a Patient with Dilated Cardiomyopathy (2009) (0)
[Three cases of Fitz-Hugh-Curtis syndrome detected in the early stage by abdominal ultrasonography]. (1998) (0)
[Surgical and non-surgical management of primary hyperparathyroidism:How do calcimimetics work?] (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Yasuhiro Takeuchi?

Yasuhiro Takeuchi is affiliated with the following schools:

Yasuhiro Takeuchi's Academic­Influence.com Rankings

Yasuhiro Takeuchi's Degrees

Similar Degrees You Can Earn

Why Is Yasuhiro Takeuchi Influential?

Yasuhiro Takeuchi's Published Works

Published Works

What Schools Are Affiliated With Yasuhiro Takeuchi?

Yasuhiro Takeuchi's AcademicInfluence.com Rankings